V-Go Insulin Delivery System Versus Multiple Daily Insulin Injections for Patients With Uncontrolled Type 2 Diabetes Mellitus

Winter, Abigail J.; Lintner, Michaela; Knezevich, Emily

doi:10.1177/1932296815580361

Cited by 28 publications

(26 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One of the most simplistic of the patch systems is the V-Go TM device designed by Valeritas, Inc. as it does not require batteries, programming or a hand-held remote [38]. The daily disposable V-Go TM insulin delivery device is designed to deliver a 24-hour cover of both basal and bolus insulin and is suitable for patients on multiple daily injections.…”

Section: Subcutaneous Insulin Patch-pump Systemsmentioning

confidence: 99%

See 1 more Smart Citation

A review of non-invasive insulin delivery systems for diabetes therapy in clinical trials over the past decade

Easa

Alany

Carew

et al. 2019

Drug Discovery Today

View full text Add to dashboard Cite

At present, the main form of insulin administration is the invasive subcutaneous route, and this for many individuals means managing their glucose levels with multiple daily injections, which is both painful and difficult to administer chronically. To increase patient compliance, products are slowly reaching the market that are more patient friendly such as the insulin patch-pump systems, like Omnipod and V-Go, but also the inhaled insulin Afrezza® and the buccal insulin Oral-lyn™. This review outlines the history of insulin, the various options that are currently available in practice for insulin delivery, and the non-invasive delivery systems that have managed to enter the different stages of clinical trials in the past decade.

show abstract

Section: Subcutaneous Insulin Patch-pump Systemsmentioning

confidence: 99%

“…The meal-time administration of insulin is initiated by the patient by two simple sequential clicks of the bolus ready and bolus delivery buttons. The device was launched by Valeritas, Inc. in May 2012 [38].…”

Section: Subcutaneous Insulin Patch-pump Systemsmentioning

confidence: 99%

A review of non-invasive insulin delivery systems for diabetes therapy in clinical trials over the past decade

Easa

Alany

Carew

et al. 2019

Drug Discovery Today

View full text Add to dashboard Cite

show abstract

“…Patients have reported the V-Go device to be discreet and easy to use, and the basal and bolus capability of the device eliminates the need for multiple injections, all of which may help improve patient compliance with insulin therapy [8,9]. Evidence has supported an improvement in glycemic control with V-Go [9][10][11][12][13][14][15][16][17]; however, prospective data are lacking, and further evidence is warranted to understand the impact of V-Go across a wide range of patients.…”

Section: Key Pointsmentioning

confidence: 99%

Effectiveness of V-Go® for Patients with Type 2 Diabetes in a Real-World Setting: A Prospective Observational Study

Grunberger

Rosenfeld

Bode

et al. 2019

Drugs - Real World Outcomes

View full text Add to dashboard Cite

Background V-Go is a wearable, patch-like, 24-h insulin delivery device that delivers both a continuous preset basal rate and on-demand bolus dosing. The aim of this study was to observe glycemic control, insulin dosing, and hypoglycemia risk in patients switched to V-Go in a real-world setting. The primary objective was to compare change in mean hemoglobin A1c (HbA1c) from baseline to the end of V-Go use. Methods This prospective, open-label, multicenter study recruited patients with type 2 diabetes (T2D) and suboptimal glycemic control (HbA1c ≥ 7%) across 28 centers. Efficacy analyses were conducted for all patients with a post-baseline HbA1c and results stratified based on prior antihyperglycemic medication therapies. Insulin dosing was at the discretion of the health care provider and the protocol did not mandate glycemic targets. Treatment satisfaction surveys were utilized to gain patient feedback on the use of V-Go. Results One hundred eighty-eight patients were enrolled in the study, among whom 140 patients had a valid post-baseline HbA1c and were included in the primary efficacy analysis. Use of V-Go resulted in a change of − 0.64%; (P = 0.003) in HbA1c from baseline, and in those prescribed insulin, the total daily dose of insulin was decreased by 12 units/day (P < 0.0001). Twenty-two patients (12%) reported hypoglycemic events (≤ 70 mg/dL), with an event rate of 1.51 events/ patient/year. Conclusion In a T2D population with suboptimal HbA1c, initiating V-Go therapy in a real-world setting significantly improved glycemic control and led to significant insulin dose reductions. ClinicalTrial.gov registry identifier: NCT01326598.

show abstract

“…Another insulin delivery option is a disposable patch-like device, which provides a continuous, subcutaneous infusion of rapid-acting insulin (basal), as well as 2-unit increments of bolus insulin at the press of a button (7).…”

mentioning

confidence: 99%

7. Diabetes Technology: Standards of Medical Care in Diabetes—2019

2018

Diabetes Care

173

View full text Add to dashboard Cite

The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC. Diabetes technology is the term used to describe the hardware, devices, and software that people with diabetes use to help manage blood glucose levels, stave off diabetes complications, reduce the burden of living with diabetes, and improve quality of life. Historically, diabetes technology has been divided into two main categories: insulin administered by syringe, pen, or pump, and blood glucose monitoring as assessed by meter or continuous glucose monitor. More recently, diabetes technology has expanded to include hybrid devices that both monitor glucose and deliver insulin, some automatically, as well as software that serves as a medical device, providing diabetes self-management support. Diabetes technology, when applied appropriately, can improve the lives and health of people with diabetes; however, the complexity and rapid change of the diabetes technology landscape can also be a barrier to patient and provider implementation. To provide some additional clarity in the diabetes technology space, the American Diabetes Association is, for the first time, adding a dedicated section on diabetes technology to the "Standards of Medical Care in Diabetes." For this first writing, the section will focus on insulin delivery and glucose monitoring with the most common devices currently in use. In future years, this section will be expanded to include software as a medical device, privacy, cost, technology-enabled diabetes education and support, telemedicine, and other issues that providers and patients encounter with the use of technology in modern diabetes care. INSULIN DELIVERY Insulin Syringes and Pens Recommendations 7.1 For people with diabetes who require insulin, insulin syringes or insulin pens may be used for insulin delivery with consideration of patient preference, insulin type and dosing regimen, cost, and self-management capabilities. B 7.2 Insulin pens or insulin injection aids may be considered for patients with dexterity issues or vision impairment to facilitate the administration of accurate insulin doses. C

show abstract

V-Go Insulin Delivery System Versus Multiple Daily Insulin Injections for Patients With Uncontrolled Type 2 Diabetes Mellitus

Cited by 28 publications

References 3 publications

A review of non-invasive insulin delivery systems for diabetes therapy in clinical trials over the past decade

A review of non-invasive insulin delivery systems for diabetes therapy in clinical trials over the past decade

Effectiveness of V-Go® for Patients with Type 2 Diabetes in a Real-World Setting: A Prospective Observational Study

7. Diabetes Technology: Standards of Medical Care in Diabetes—2019

Contact Info

Product

Resources

About